Zosano Pharma (NASDAQ:ZSAN) posted its earnings results on Thursday. The biotechnology company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.16), Morningstar.com reports.
ZSAN stock opened at $5.07 on Friday. Zosano Pharma has a fifty-two week low of $1.85 and a fifty-two week high of $21.45.
Separately, ValuEngine upgraded Zosano Pharma from a “hold” rating to a “buy” rating in a research note on Friday, February 22nd.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ZSAN. Aisling Capital Management LP acquired a new position in Zosano Pharma during the fourth quarter worth approximately $3,392,000. Nexthera Capital LP increased its position in Zosano Pharma by 47.7% during the third quarter. Nexthera Capital LP now owns 1,033,759 shares of the biotechnology company’s stock worth $4,228,000 after buying an additional 333,759 shares during the period. Telemetry Investments L.L.C. increased its position in Zosano Pharma by 37.8% during the fourth quarter. Telemetry Investments L.L.C. now owns 219,040 shares of the biotechnology company’s stock worth $464,000 after buying an additional 60,069 shares during the period. Dimensional Fund Advisors LP acquired a new position in Zosano Pharma during the third quarter worth approximately $121,000. Finally, Northern Trust Corp acquired a new position in Zosano Pharma during the second quarter worth approximately $119,000. 46.57% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “Zosano Pharma (ZSAN) Issues Quarterly Earnings Results, Misses Expectations By $0.16 EPS” was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another site, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this article can be read at https://www.tickerreport.com/banking-finance/4222804/zosano-pharma-zsan-issues-quarterly-earnings-results-misses-expectations-by-0-16-eps.html.
Zosano Pharma Company Profile
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine.
See Also: What are defining characteristics of a correction?
Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.